Royal Bank Of Canada Kinnate Biopharma Inc. Transaction History

Royal Bank Of Canada

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$2.24 - $2.66 $24 - $29	11 Added 366.67%	14 $0
Q4 2023 Feb 14, 2024	SELL	$1.07 - $2.5 $24 - $57	-23 Reduced 88.46%	3 $0
Q3 2023 Nov 14, 2023	SELL	$1.38 - $3.31 $661 - $1,585	-479 Reduced 94.85%	26 $0
Q2 2023 Aug 14, 2023	SELL	$2.33 - $6.84 $3,807 - $11,176	-1,634 Reduced 76.39%	505 $1,000
Q1 2023 May 15, 2023	SELL	$3.46 - $7.98 $10,850 - $25,025	-3,136 Reduced 59.45%	2,139 $13,000
Q4 2022 Feb 14, 2023	BUY	$5.26 - $12.19 $23,243 - $53,867	4,419 Added 516.24%	5,275 $32,000
Q3 2022 Nov 14, 2022	BUY	$9.86 - $15.76 $1,893 - $3,025	192 Added 28.92%	856 $10,000
Q2 2022 Aug 15, 2022	SELL	$7.43 - $13.0 $10,535 - $18,434	-1,418 Reduced 68.11%	664 $8,000
Q1 2022 May 16, 2022	SELL	$7.73 - $17.99 $27,085 - $63,036	-3,504 Reduced 62.73%	2,082 $24,000
Q4 2021 Feb 14, 2022	BUY	$16.5 - $25.48 $31,729 - $48,998	1,923 Added 52.5%	5,586 $100,000
Q3 2021 Nov 15, 2021	BUY	$17.81 - $24.87 $29,404 - $41,060	1,651 Added 82.06%	3,663 $85,000
Q2 2021 Aug 16, 2021	BUY	$22.19 - $31.55 $44,646 - $63,478	2,012 New	2,012 $48,000

292K

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.